Health Care • Biotechnology: Pharmaceutical Preparations
$44.89 ▼ -0.45
(-0.99%)
MKT CAP: $7.61B • VOL: 2.16M
52W L $27 52W H $56
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$38
MEDIAN
$50
MEAN
$51
HIGH
$61
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE ALKS TAPE
ALKS // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $54.32 | $51.62 | 2025-02-14 | $40.85 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $56.56 | $52.97 | 2025-02-06 | $42.20 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $51.17 | $49.38 | 2025-01-29 | $43.09 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $45.79 | — | 2025-01-17 | $43.99 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $39.50 | $42.65 | 2025-01-09 | $39.95 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $53.42 | $46.69 | 2024-12-18 | $39.05 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $43.54 | $45.34 | 2024-12-04 | $41.75 | -4.3% | 48% | C |